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VaccineAutoimmune disorders occur when the immune system abnormally recognizes and attacks self-molecules. Den-
dritic cells (DCs) play a powerful role in initiating adaptive immune response, and are therefore a recent target for
autoimmune therapies. N-Phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide (PHCCC), a small
molecule glutamate receptor enhancer, alters how DCs metabolize glutamate, skewing cytokine secretion to
bias T cell function. These effects provide protection in mouse models of multiple sclerosis (MS) by polarizing
T cells away from inﬂammatory TH17 cells and toward regulatory T cells (TREG)whenmice receive daily systemic
injections of PHCCC. However, frequent, continued treatment is required to generate and maintain therapeutic
beneﬁts. Thus, the use of PHCCC is limited by poor solubility, the need for frequent dosing, and cell toxicity.
We hypothesized that controlled release of PHCCC from degradable nanoparticles (NPs) might address these
challenges by altering DC function to maintain efﬁcacy with reduced treatment frequency and toxicity. This
idea could serve as a new strategy for harnessing biomaterials to polarize immune function through controlled
delivery of metabolic modulators. PHCCC was readily encapsulated in nanoparticles, with controlled release of
89% of drug into media over three days. Culture of primary DCs or DC and T cell co-cultures with PHCCC NPs
reduced DC activation and secretion of pro-inﬂammatory cytokines, while shifting T cells away from TH17 and
toward TREG phenotypes. Importantly, PHCCC delivered to cells in NPs was 36-fold less toxic compared with
soluble PHCCC. Treatment ofmicewith PHCCCNPs every three days delayed disease onset and decreased disease
severity compared with mice treated with soluble drug at the same dose and frequency. These results highlight
the potential to promote tolerance through controlled delivery ofmetabolicmodulators that alter DC signaling to
polarize T cells, and suggest future gains that could be realized by engineeringmaterials that provide longer term
release.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Polymeric nanoparticles (NPs) are ubiquitous in nanotechnology
owing in part to the ability of thesematerials to encapsulate and control
the release of hydrophobic, small molecule drugs [1]. Recently, this
approach has become of great interest for polarizing immune cells
(e.g., T cells) toward functions tailored for speciﬁc vaccine, cancer, and
immunotherapy applications [2–4]. Here we investigated a new idea
for driving this polarization through controlled release of small mole-
cules that control immune cellmetabolism to promote tolerance and re-
strain autoimmunity. In these studies we employed a well-understood
NP platform to test if controlled release of these drugs would alterngineering, 2212 Jeong H. Kim
tes.
. This is an open access article underdendritic cell (DC) function, promote regulatory T cells, andmore effec-
tively control disease in mouse models of autoimmunity with less fre-
quent dosing and reduced toxicity.
Autoimmune disease occurs when the adaptive immune system
recognizes and attacks self molecules. Multiple sclerosis (MS) is an
autoimmune disease in which myelin — a protein that insulates neu-
rons — is attacked, causing inﬂammation and neurodegeneration in the
central nervous system (CNS). Some of the key effector cell populations
that drive these detrimental effects are inﬂammatory subsets of
myelin-reactive CD4+ T cells [5–7]. Further, high levels of glutamate
are present in the central nervous system during MS, leading to a state
of excitotoxicity that exacerbates inﬂammation and depletes oligoden-
drocytes— the cells responsible for remyelinating neurons [8,9]. Theme-
tabotropic glutamate receptor (mGluR) family helps control these
effects, resulting in inﬂammation or protection against excitotoxicity, de-
pending on the relative presence and activity of each mGluR receptor in
the CNS during disease [8–11]. In particular, metabolism of glutamatethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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rons and kainate mediated toxicity in oligodendrocytes [11,12].
In addition to serving as a neurotransmitter, glutamate also func-
tions as an immunomodulator by interacting with glutamate receptors
expressed on the surface of DCs or other immune cells [13]. DCs play a
key role in initiating adaptive immunity by processing and presenting
exogenous antigens, or in the case of autoimmune diseases such as
MS, self antigens (e.g., myelin). Presentation of these antigens to a
cognate T cell drives antigen-speciﬁc proliferation and differentiation.
The magnitude and type of T cell response is dictated in part by the
activation and inﬂammatory state of DCs during the formation of an im-
mune synapse with a T cell [14]. For example, suppression of DC activa-
tion can induce secretion of regulatory cytokines that diminish T cell
expansion and shift the phenotypes toward regulatory T cells (TREG)
and away from inﬂammatory T cells (e.g., TH17) [15–17].
During inﬂammation, DCs release glutamate that regulates T cell
activation and proliferation by binding glutamate receptors on DCs
and T cells [13,18,19]. The identity and abundance of the mGluRs that
are bound by glutamate alters cAMP levels, modulating the balance of
inﬂammatory and regulatory cytokines that direct the resulting im-
mune response. This mechanism has stimulated interest in controlling
glutamate receptor signaling as one route to regulate immune cell
function in new therapies for MS [19–21]. The Di Marco group re-
cently demonstrated that mGluR4 is expressed at high levels on
DCs and exerts an immunoregulatory function by showing that DCs
with defective mGluR4 signaling preferentially polarize T cells to
inﬂammatory TH17 phenotypes. This work further revealed that
N-Phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide
(PHCCC), a small molecule positive allosteric modulator of mGluR4, can
bias T cell function toward tolerance during autoimmunity in mice [12,
19]. Prophylactic treatment of mice with PHCCC during Experimental
Autoimmune Encephalomyelitis (EAE) – a mouse model of MS –
inhibited clinical symptoms of neuroinﬂammation by inducing regula-
tory cytokine proﬁles in DCs that promoted TREGS and reduced TH17
cells [10]. However, the use of PHCCC is hindered by poor solubility
and a short half-life [22], with neurological symptoms and paralysis
returning within one day after daily systemic injections were stopped
[19].
To address these challenges, we hypothesized that controlled release
of PHCCC might maintain or improve efﬁcacy while offering less
frequent dosing and reduced toxicity. Our studies revealed that NPs
were readily endocytosed by DCs and reduced inﬂammatory cytokines.
Strikingly, these effects were achieved with a 36-fold decrease in toxic-
ity compared to soluble PHCCC. During co-culture with myelin-speciﬁc
T cells, DCs treated with PHCCC NPs reduced TH17 cells and increased
TREGS, while reducing inﬂammatory cytokines. Treatment of mice with
PHCCC NPs every three days delayed disease onset and decreased
severity compared with soluble drug. These results demonstrate a
biomaterial-based approach to promote tolerance by harnessing con-
trolled release for modulation of DC metabolic function.
2. Materials and methods
2.1. Materials
PHCCC was purchased from Tocris Bioscience. Poly(lactide-
co-glycolide) (PLGA, 30,000–60,000 MW, 50:50 lactide:glycolide),
polyvinyl alcohol (PVA) (MW 89,000–98,000), acetone, wheat germ
agglutinin Texas Red conjugate, ethylenediaminetetraacetic acid
(EDTA), sesame oil, and bovine serum albumin (BSA) were purchased
from Sigma. Dimethyl-sulfoxide (DMSO) was purchased from Fisher
scientiﬁc. Myelin oligodendrocyte glycoprotein (MOG35–55) and
SIINFEKL peptides were synthesized by Genscript. Antibodies for ﬂow
cytometry were purchased from BD biosciences and included CD11c
APC-Cy7, CD40 PE, CD86 PE-Cy7, CD80 APC, CD4 APC-Cy7, CD4 FITC,
RORγ PE and FoxP3 Alexa Fluor 647. Anti-mouse H-2 kb bound toSIINFEKL PE-Cy7 was purchased from Biolegend. 4′,6-diamidino-2-
phenylindole (DAPI), DiO, lipopolysaccharide (LPS) and Hoechst nucle-
ar stain were purchased from Invitrogen. DC and T cell culture media
was RPMI 1640 base media (Lonza) supplemented with 10% fetal bo-
vine serum (Corning), 100 μg/100 U penicillin–streptomycin (Lonza),
10 mM HEPES (Thermo Scientiﬁc), 2 mM L-glutamine (Lonza), 55 μM
beta-mercaptoethanol (MP Biomedical), and non-essential amino
acids (1×, Thermo Scientiﬁc).
2.2. Cells and mice
For in vitro studies, DCs weremagnetically isolated from the spleens
of naïve, female, C57BL/6J mice (4 weeks) using CD11c positive selec-
tionmicrobeads (Miltenyi). CD4+ T cells were isolated from the spleens
of transgenic female, C57BL/6-Tg(Tcra2D2,Tcrb2D2)1Kuch/J (2D2)
mice using negative magnetic cell isolation (Stemcell Technologies).
CD4+ T cell receptors in this strain recognize and respond to MOG pre-
sented via the MHC-II complex [23]. EAE was induced in 10 week old,
female, C57BL/6J mice as described below. All animal care and experi-
ments were carried out using protocols approved and overseen by the
University of Maryland IACUC committee.
2.3. Particle synthesis and characterization
PLGA NPs encapsulating PHCCC were synthesized by nano-
precipitation. The solvent phase was prepared by dissolving 25 mg of
PLGA in 1.5 mL acetone. For samples loaded with PHCCC, this polymer
solution was transferred to a vial containing the appropriate mass of
dried PHCCC. For samples loaded instead with DiO, 5 μL of 1 μM DiO
solution was added to the polymer solution. The non-solvent phase
consisted of 20 mL deionized water with 0–2% PVA. The solvent phase
was then uniformly injected through a 31 g needle under the surface
of the non-solvent phase while mixing with a magnetic stir bar. The
solvent was evaporated for 3 h, leaving a suspension of stabilized NPs.
The suspension was poured through a 40 μm cell strainer then centri-
fuged for 75 min at 4 °C at 3000 g. The supernatant was decanted and
the NPs were resuspended in deionized water.
To measure PHCCC encapsulation, NPs were dried and dissolved in
DMSO. The absorbancewas thenmeasured at 300nmon aUV–VIS spec-
trophotometer and corrected by subtracting the absorbance valuemea-
sured for emptyNPs dissolved at the samemass concentration inDMSO.
Absorbance values were compared to a PHCCC standard curve to deter-
mine amass concentration. Particle size distributionsweremeasured by
laser diffraction using a Horiba Partica LA 950V2.
To measure release kinetics, known concentrations of PHCCC NPs
were incubated at 37 °C in RPMI 1640 media under sink conditions
to eliminate release effects arising from saturated drug solution. At
each interval PHCCC NPs were centrifuged at 18,000 g for 5 min, and
PHCCC concentration in the supernatants was determined by UV–VIS
spectrophotometry as above. Particles were then resuspended in
media and returned to incubation at 37 °C. The cumulative PHCCC re-
leased was calculated at each time and normalized to the total loading
to calculate the percent of PHCCC released.
2.4. Flow cytometry
Flow cytometry was carried out on a FACSCantoII ﬂow cytometer
(BD Biosciences). Cells were ﬁrst detached from the 96 well culture
plates with cold 10 mM EDTA, then washed with 1% BSA in PBS. Cells
were blocked by incubation at room temperature in 20 μg/mL rat anti-
mouse CD16/CD32 (BD Biosciences) for 10 min. Blocked cells were
stained with antibodies diluted in PBS + 1% BSA for 20 min at room
temperature protected from light. Cells were then washed twice with
PBS+1%BSA and either resuspended in PBS+1%BSA (with orwithout
5 μg/mL DAPI) for immediate analysis, or ﬁxed and stained for intracel-
lular markers. For intracellular staining, cells were resuspended in
Table 1
Properties of PHCCC NPs synthesized with different input ratios of PHCCC to PLGA.
PHCCC:polymer
input ratio
PHCCC
input
Polymer
input
Loading level Diameter
(mg) (mg) (mg) (μg PHCCC/mg
particle)
(nm)
0 0 25 N/A 125.2 ± 60.2
0.04 1 25 25.4 ± 12.2 132.9 ± 36.4
0.12 3 25 44.7 ± 13.3 185.9 ± 33.7
0.2 5 25 73.2 ± 25.9 148.5 ± 47.1
0.4 10 25 78.3 ± 12.9 114.4 ± 42.2
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2 h at 4 °C in the dark. Cells were thenwashed twicewith FoxP3 perme-
abilization buffer (Ebioscience) and resuspended in antibodies against
the appropriate intracellularmarkers diluted in FoxP3 permeabilization
buffer. Cells were incubated at 4 ° C for 40min in the dark. Stained cells
were washed twice with FoxP3 permeabilization buffer then resus-
pended in PBS + 1% BSA for analysis.
2.5. Particle uptake and toxicity studies
Isolated DCswere plated in ﬂat bottom 96well plates and incubated
in media with the speciﬁed concentrations of DiO NPs for 90 min. Cells
were washed with PBS to remove free NPs, and then detached using
cold, 10 mM EDTA. Detached cells were washed with cold PBS + 1%
BSA, then resuspended inDAPI (5 μg/mL) in PBS+1%BSA.DCswere an-
alyzed by ﬂow cytometry to determine the percentages of cells positive
for DiO (particles). For analysis of particle uptake bymicroscopy, splenic
CD11c+ DCs were plated in 35mmdishes and incubated in media with
DiO NPs for 90 min. Cells were washed with PBS to remove free NPs,
then ﬁxed with 4% paraformaldehyde for 15 min at 37 °C. Cell mem-
branes were stained at room temperature in the dark for 10 min with
5 μg/mL wheat germ agglutinin Texas Red conjugate in PBS. The cells
were then washed with PBS, labeled with Hoechst nuclear stain diluted
to 2 μg/mL in PBS. Cells were imaged using a Leica SP5 X laser scanning
confocal microscope with a 63× objective.
To analyze toxicity of soluble PHCCC or PHCCC delivered in NP
format, CD11c+ cells isolated from splenocytes (1 × 105 cells/well)
were stimulated with LPS (1 μg/mL) and treated with equivalent
concentrations of PHCCC delivered in soluble or NP format. After 18 h
toxicity was analyzed by ﬂow cytometry by staining with DAPI and
quantifying the percentage of DAPI− events. Relative viability was cal-
culated by normalizing the percent of viable cells to the value of the
untreated LPS stimulated control. The fold-decrease in toxicity was cal-
culated by dividing the relative viability of cells treatedwith PHCCCNPs
by the value for cells treated with soluble PHCCC at 400 μM.
2.6. DC activation, antigen presentation and cytokine secretion
For analysis of DC activation and cytokine secretion, CD11c+ cells
isolated from splenocytes (1 × 105 cells/well) were stimulated with
LPS (1 μg/mL) and left untreated or treated with soluble PHCCC
(40 μM), PHCCC NPs, or empty NPs using equivalent particle masses.
For soluble PHCCC controls, PHCCC was dissolved in DMSO to 20 mM
then diluted to a ﬁnal concentration of 40 μM in media. DMSO concen-
tration in the well was 0.2% (v/v). After 18, 44 and 68 h, cells and cell
culture supernatants were collected. IL-6 and IL-10 concentrations in
the supernatants were determined by ELISAs (BD Biosciences). The col-
lected cell pellets were stained as above for viability (DAPI−), CD11c
(APC-Cy7) and activation/costimulatory markers (i.e., FITC I-A/I-E, PE
CD40, PE-Cy7 CD86, APC CD80). Cells were gated under DAPI−/
CD11c+ negative events.
For analysis of DC antigen presentation, DCs stimulated with LPS
were treated with PHCCC, PHCCC NPs, and empty NPs as in DC activa-
tion studies. After 18 h, cells were incubated for 2 h with SIINFEKL
peptide (5 μg/mL), or withMOG35–55 (5 μg/mL) as an irrelevant peptide
control. Cells were then stained for presentation of SIINFEKL via the
H-2 kb complex using an antibodywhich binds SIINFEKLwhenpresented
in H-2 kb. Cells were gated under CD11c+/DAPI−.
2.7. Co-culture of DCs with transgenic 2D2 T cells
IsolatedDCs (1× 105 cells/well) were stimulatedwith LPS (1 μg/mL)
and MOG (10 μg/mL) and treated with soluble PHCCC (40 μM), PHCCC
NPs, or empty NPs. After 18 h, splenic CD4+ T cells isolated from 2D2
mice (3 × 105 cells/well) were added to the DC culture. After an addi-
tional 2 days, supernatants were collected and IFNγ concentrationswere measured by ELISA (BD Bioscience). Cells from these cultures
were stained for CD4 and CD25 surface markers, along with FoxP3
and RORγ transcription factors as markers for TREGS (CD4+/CD25+/
FoxP3+) and inﬂammatory TH17 cells (CD4+/RORγ+), respectively.
2.8. T cell proliferation studies
For proliferation studies, splenic CD4+T cells isolated from2D2mice
were incubated with carboxyﬂuorescein succinimidyl ester (CSFE) be-
fore addition to DCs treated with LPS, peptide, and particles as above.
The T cells were labeled by resuspension in media at 50 × 106 cells/mL
then incubation in CSFE at a ﬁnal concentration of 5 μM for 5 min at
room temperature. Cells were washed four times with media, then
added to the DC cultures. Cells were collected 72 h later and analyzed
by ﬂow cytometry to determine the extent of T cell proliferation
(i.e., CSFE levels among CD4+/DAPI− cells). Analysis was performed
using FlowJo software (Treestar).
2.9. EAE induction and treatment with PHCCC NPs
EAE was induced in 10 week old C57BL/6 mice as previously de-
scribed [24,25]. Brieﬂy, mice were immunized with two subcutaneous
(s.c.) injections of emulsions prepared from complete Freund's adjuvant
(CFA) and 100 μg of MOG35–55 in killed mycobacterium tuberculosis
H37Ra (200–500 μg). Subsequently, 200 ng of pertussis toxin in
100 μL of PBS was injected intra-peritoneal (i.p.) on the day of immuni-
zation and again the following day.
Soluble PHCCC, PHCCCNPs (each 3mg/kgwith respect to drug dose)
were administered s.c. at the tailbase every 3 days or every 5 days begin-
ning on the day of EAE induction (day 0). For soluble treatment, PHCCC
was dissolved in sesame oil [19] and PHCCC NPs were suspended in de-
ionizedwater. EmptyNPs at the samemass as the PHCCCNP treatments
were included as controls. Micewereweighed and scored daily for signs
of disease using an accepted clinical pathology scoring scale: 0, no
symptoms; 1, limpness in entire tail; 2 weakness in hind legs; 3, paral-
ysis of hind legs or paralysis of one front leg and one hind leg; 4, mori-
bund. Mice were euthanized according to deﬁned endpoints if a score
of 4.5 was reached, upon a score of 4.0 for 2 days, or upon 25% weight
loss (with respect to initial weight).
3. Results
3.1. PHCCC is encapsulated into nanoparticles at high levels and released
over three days
Toward the goal of maintaining drug function while reducing toxic-
ity and frequency of treatment, we ﬁrst developed protocols to synthe-
size PHCCC-loaded NPs by nanoprecipitation. PHCCC was successfully
encapsulated in NPs at high levels, with PHCCC loading levels correlated
with increasing ratios of drug to polymer input. Loading was optimal at
a drug:polymer input ratio of 0.2, which resulted in a drug loading level
of 73.2 ± 25.9 μg of PHCCC per mg of NPs (Table 1). Further increasing
the drug to polymer ratio to 0.4 or higher did not result in any further
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with mean diameters ranging from 114–186 nm depending on the
drug to polymer ratio (Fig. 1A and B). To examine the release kinetics
of PHCCC from NPs, particles were incubated in media at 37 °C. PHCCC
NPs released 66.3% of drug over the ﬁrst 4 h, followed by a slower
release rate that accounted for release of 89.1% of total encapsulated
drug after 72 h (Fig. 1C).
3.2. NPs are efﬁciently internalized by DCs with reduced toxicity compared
to soluble PHCCC
To test the ability of DCs to internalize NPs, ﬂuorescently-labeled
empty NPs were incubated with CD11c+ splenic DCs for 90 min. Flow
cytometry analysis of these samples revealed a dose dependent uptake
of NPs with up to 58.4 ± 2.8% of live, CD11c+ cells positive for NPs
(Fig. 1D). Visualization of cells by confocal microscopy conﬁrmed
these results, showing punctate NPs distributed throughout the cytosolic
regions of DCs (Fig. 1E, green signal). To assess the toxicity of PHCCC on
immune cells, we stimulated DCs with LPS, along with varying doses of
PHCCC in soluble form or loaded in NPs. After 18 h, only 2.2% of cells
treated with LPS and soluble PHCCC remained viable relative to cells
treated with LPS alone (Fig. 1F). Strikingly, 83.6% of DCs remained viable
following treatmentwith LPS and an equivalent concentration of PHCCC
in NP form, representing a 36-fold reduction in toxicity (Fig. 1F).
3.3. PHCCC NPs alter DC cytokine secretion proﬁles
To determine what range of drug input levels in NPs would alter DC
function, DCs were stimulated with LPS and incubated with a ﬁxed
dose of PHCCC loaded in NPs that were prepared using different
drug:polymer ratios (Fig. 2, green bars). Empty NP (Fig. 2, gray bars)
controls were prepared at the same mass of NPs (i.e., polymer) used
for PHCCC NPs to conﬁrm that the effect of PHCCC NPs was attributableFig. 1.NPs synthesized by nanoprecipitation are internalized by DCs and eliminate toxicity obs
tribution of PHCCC NPs synthesized with 2% PVA and a drug to polymer ratio of 0.2. (C) In vitr
ﬂuorescent NPs, and the percent of DCs positive for NP uptake was quantiﬁed by ﬂow cytome
of NPs (green) within cells. DCs were stained with a Texas Red wheat germ agglutinin conjug
LPS (1 μg/mL) and treated with PHCCC in soluble or NP form. Viability relative to LPS stimulate
lected in triplicate and are representative of 3 similar experiments.to encapsulated PHCCC. The levels of IL-6 and IL-10 secretion were then
measured in the supernatants to determine if PHCCC NPs reduced the
inﬂammatory effects caused by LPS treatment. IL-6 levels generally in-
creased over the 3 day incubation, but at each time point, DCs treated
with LPS and aﬁxeddrug dose loaded in PHCCCNPs, caused a signiﬁcant
reduction in IL-6 secretion compared with cells treated with LPS only
(Fig. 2A–C). These reductionswere not as large as those observed in sam-
ples treated with soluble PHCCC. In contrast, empty particles generally
did not cause a signiﬁcant change in IL-6 level. However, at empty parti-
cle masses equivalent to those used for the lowest drug:polymer ratio
(i.e., highest polymer mass), empty NP controls had a modest effect on
IL-6 secretion. PHCCC also decreased IL-10 secretion, but the kinetics of
this reduction after treatment with soluble PHCCC or PHCCCNPswas de-
layed compared with the timeline observed for IL-6 (Fig. 2D–F). The ef-
fects of PHCCC NPs were evident at 44 h and 68 h, but not at the earlier
time point of 18 h where no differences were observed between empty
NPs and PHCCC NPs (Fig. 2D–F). Control studies with the same dilute
levels of DMSO (0.2%) used to solubilize free PHCCC conﬁrmed this vehi-
cle had no effect on toxicity, cytokine levels, or activation, comparedwith
wells treated with media or LPS without DMSO.
A further optimization studywas performed by varying the stabilizer
(i.e., PVA) concentration for NPs prepared at a drug:polymer ratio of 0.2
(Fig. S1). This ratio was selected since PHCCC loadingwasmost efﬁcient
using this drug input ratio, and minimal background effects were ob-
served from empty particles. In the stabilizer studies, the effect of
empty NPs on cytokine secretionwasminimized at a PVA concentration
of 2% (Fig. S1). Therefore particles synthesized using these two parame-
ters were chosen for all subsequent studies.
Using the optimized particle formulation, we next identiﬁed a dos-
ing range where PHCCC NPs modulate DC function by stimulating DCs
with LPS and treating with a range of PHCCC NP doses. For IL-6, a dose
dependent response was observed at each time point, with PHCCC
NPs at higher concentrations causing larger reduction in IL-6 secretionerved from soluble PHCCC. (A) SEM image of PHCCC NPs. (B) Histogram showing size dis-
o release kinetics of PHCCC NPs. (D) Primary splenic DCs were incubated for 90 min with
try. (E) Confocal microscopy image of DCs treated as in (D), demonstrating colocalization
ate (red) and Hoechst nuclear stain (blue). (F) Primary splenic DCs were stimulated with
d cells was quantiﬁed by DAPI staining and analysis by ﬂow cytometry. All data were col-
Fig. 2. Impact of PHCCC loading in NPs on DC cytokine secretion. CD11c+ cells isolated from spleens were stimulated with LPS (1 μg/mL) and treated with soluble PHCCC or PHCCC NPs
(100 μMwith respect to drug) synthesized by ﬁxing polymermass and varying drug input (drug:polymer ratio). Cells treated with equivalent masses of empty NPswere also included as
controls. Supernatants were collected and the concentrations of IL-6 (A–C) and IL-10 (D–F) were measured by ELISA at 18 h (A, D), 44 h (B, E), and 68 h (C, F). Samples were prepared in
triplicate and data are representative of results from at least 3 similar experiments.
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was less clear at the 18 h time point (Fig. 3D–F). Empty NP controls did
not signiﬁcantly suppress IL-6, but caused a modest decrease in IL-10Fig. 3. PHCCCNPs alter cytokine secretion by DCs in a dose dependentmanner. CD11c+ cells iso
NPs at decreasing doses, or equivalentmasses of empty NPs. Supernatantswere collected and th
(B, E), and 68 h (C, F). Samples were prepared in triplicate and data are representative of resullevels at 44 h and 68 h compared with LPS. However, at all three time
points PHCCC NPs signiﬁcantly decreased cytokine secretion compared
to empty NPs.lated from spleens stimulatedwith LPS (1 μg/mL)were treatedwith soluble PHCCC, PHCCC
e concentrations of IL-6 (A–C) and IL-10 (D–F)weremeasured by ELISA at 18 h (A, D), 44 h
ts from at least 3 similar experiments.
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T cell proliferation andphenotype (e.g., TH17 vs. TREG) are dependent
on the levels and balance of antigen and co-stimulatory signals present-
ed by DCs. To test the hypothesis that PHCCC NPs would decrease stim-
ulatory cues presented by DCs, DCs were stimulated with LPS and left
untreated or treated with PHCCC in soluble or NP form. After 18 h,
ﬂow cytometry was used to assess CD40, CD80, and CD86 expression,
as well as loading and presentation of a common antigenic peptide by
theMHC-I pathway. As shown in Fig. 4A–C (green bars), PHCCCNPs sig-
niﬁcantly decreased CD40, CD80 and CD86 expression on DCs relative to
DCs cultured onlywith LPS. These effects were dose dependent andwere
comparable to the reduction caused by soluble PHCCC. Compared with
LPS-treated positive controls, emptyNPs did not signiﬁcantly alter DC ac-
tivation at any concentration (Fig. 4A–C, gray bars), though for CD40, a
slight reduction in expression was observed at the highest doses.
To assess the impact of PHCCC NPs on antigen presentation, DCs
were incubated with LPS, soluble PHCCC or PHCCC NPs, and SIINFEKL
peptide — a common model antigen derived from ovalbumin. After
20 h, cells were stained with an antibody that binds SIINFEKL only
when presented in MHC-I (H-2 kb). While 81.3 ± 0.7% of cells treated
with LPS and SIINFEKL presented this antigen viaMHC-I (Fig. 4D), treat-
ment with PHCCC NPs reduced SIINFEKL presentation to 30.3% ± 3.0%,
depending on NP dose (Fig. 4D, green bars). The magnitude of this
reduction was signiﬁcant compared with cells lacking PHCCC treat-
ments, but less pronounced than the reduction in SIINFEKL presentation
observed in cells treated with soluble PHCCC (11.3 ± 4.3%).
3.5. Treatment of DCs with PHCCC NPs restrains T cell expansion and
promotes TREGS
To determine if the effects of PHCCC NPs on DC activation and cyto-
kineproﬁles alter T cell differentiation,we employed a co-culturemodelFig. 4.PHCCCNPs reduceDCactivation and antigenpresentation. CD11c+ splenocyteswere stim
or equivalent masses of empty NPs. After 18 h cells were collected and the percent of live/CD11
(D) CD11c+ splenocytes were stimulated and treated with PHCCC NPs as in (A–C). After 18 h, S
cells for the percent of live/CD11c+ cells presenting SIINFEKL in H-2 kb. Samples were
experiments.in which DCs from wild-type mice were cultured with splenic CD4+
T cells isolated from transgenic 2D2 mice — a strain in which CD4+
T cell receptors are speciﬁc for a myelin autoantigen, MOG peptide
[23]. DCs were ﬁrst treated with LPS and MOG, along with soluble
PHCCC, PHCCC NPs, or empty NPs at equivalent polymer masses. After
24 h, CD4+ 2D2 splenocytes were added to the culture. 72 h later,
cells were collected and T cell proliferation, inﬂammatory cytokine se-
cretion, and polarization of TREG and TH17 phenotypes were examined.
DCs treated with PHCCC NPs drove proliferation in only 10.8 ± 0.4% of
T cells (Figs. 5A and S2, green bars), a striking decrease compared to
55.7 ± 1.9% and 68.4 ± 0.5% observed in DCs treated with soluble
PHCCC or those receiving only the stimulants (i.e., MOG+ LPS), respec-
tively (Figs. 5A and S2). Attenuation of T cell proliferation was dose de-
pendent, but was signiﬁcant even at the lowest doses of PHCCC
delivered in NP form (25.4 ± 2.2%). Equivalent masses of empty parti-
cles did not cause any signiﬁcant reduction in proliferation compared
with cells treated with LPS and MOG. Mean ﬂuorescent intensity
(MFI) analysis of these data also conﬁrmed PHCCC NPs signiﬁcantly
reduce proliferation (Fig. 5B).
Treatment of DCs with PHCCC NPs also polarized T cell phenotype,
shifting CD4+ T cells away from inﬂammatory TH17 phenotypes
(CD4+/RORγ+) and toward TREGS (CD4+/CD25+/FoxP3+) (Fig. 5C and
D, green). At the highest dose, TREG levels in wells treated with PHCCC
NPs were 5.7 ± 0.5%, compared to 3.3 ± 0.7% in samples treated with
MOG and LPS, 4.5 ± 0.6% in samples treated with soluble PHCCC, and
3.6 ± 0.7% in cells treated with equal masses of empty particles
(Fig. 5C and D). PHCCC NPs also reduced TH17 levels. In cells treated
withMOG and LPS, 82.1± 5.3% of CD4+ T cells exhibited a TH17 pheno-
type (CD4+/RORγ+), while soluble PHCCC treatment reduced RORγ
frequencies to 67.0±9.9% (Fig. 5E). PHCCCNPsmediated a dose depen-
dent response, with 58.9 ± 1.9% of cells CD4+/RORγ+ at the highest
particle dose (Fig. 5E, green). Supernatants also revealed signiﬁcant
changes in IFNγ production, with PHCCC NPs reducing IFNγ secretionulatedwith LPS (1 μg/mL) and treatedwith soluble PHCCC, PHCCCNPs at decreasingdoses,
c+ cells expressing (A) CD40, (B) CD80, (C) and CD86were quantiﬁed by ﬂow cytometry.
IINFEKL peptide (5 μg/mL) was added. Two 2 h later, ﬂow cytometry was used to analyze
prepared in triplicate and data are representative of results from at least 3 similar
Fig. 5. PHCCCNPs restrain T cell proliferation and inﬂammatory cytokines, promote TREGS, and reduce TH17 cells. CD11c+ cells isolated from spleenswere stimulatedwith LPS (1 μg/mL) in
the presence of MOG peptide (10 μg/mL), and treatedwith soluble PHCCC (40 μM), PHCCC NPs at decreasing doses, or equal masses of empty NPs. After 18 h, CD4+ splenocytes from 2D2
mice were added to culture. (A) CSFE dilutions of live/CD4+ T cells from representative co-culture samples and (B) mean ﬂuorescent CSFE intensities (MFI). (C) Gating scheme and
histograms of FoxP3 expression among CD4+/CD25+ cells (i.e., TREG). (D) Frequencies of TREGS measured for each treatment type. (E) Percentages of CD4+ cells expressing RORγ as an
indicator of TH17 cells. (F) IFNγ in supernatants. Samples were prepared in triplicate and results are representative of at least 3 studies.
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with MOG and LPS, and 8970 ± 1110 pg/mL after treatment with solu-
ble PHCCC (Fig. 5F). These studies conﬁrm PHCCC NPs reduce antigen
speciﬁc T cell proliferation and inﬂammatory cytokines, while promoting
TREGS and reducing inﬂammatory (TH17) phenotypes.
3.6. Treatment with PHCCC NPs every 3 days delays disease and reduces se-
verity in mice with EAE
We next evaluated whether controlled release of PHCCC from NPs
could provide a therapeutic beneﬁt during autoimmunity in mice, but
with less frequent or less toxic dosing than required for soluble drug.
In these studies, mice were induced with EAE, then injected subcutane-
ouslywith soluble PHCCC or PHCCCNPs every 5 days starting on the day
of EAE induction (day 0) (Fig. 6A). In this study, mice treated with solu-
ble PHCCC or PHCCC NPs exhibited identical disease progression and
severity (Fig. 6B–E), and this pathology was identical to mice induced
with EAE and treated with empty NPs (Fig. S3). We next tested a regi-
men in which mice received soluble PHCCC or PHCCC NPs every three
days (Fig. 6F). During this regimen, PHCCC NPs caused a statistically sig-
niﬁcant delay in disease onset (Fig. 6G–I) and decreased disease severity
compared tomice treatedwith soluble PHCCC or empty NPs (Figs. 6J, S3).
In groups treatedwith soluble PHCCC, 100% ofmice developed symptoms
by day 13, compared to 50% for groups treated with PHCCC NPs (Fig. 6I).
Additionally, the maximum mean clinical score over the extent of thestudy was lower in the PHCCC NP treated group, reaching a value of 2.5
compared to a score of 3.2 for mice receiving soluble PHCCC.
4. Discussion
Several recent immunotherapies have explored controlled release to
provide better or more targeted control over the function and pheno-
type of DCs or T cells. Someof the important drugs that have been tested
in this area include mycophenolic acid (MPA) [26], rapamycin [27,28],
and 2-(1′H-indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl
ester (ITE) [29]. The current study is the ﬁrst investigation of controlled
release of smallmoleculemetabolic enhancers tomodulate immune cell
function and restrain autoimmunity. Since glutamate is expressed at
high, toxic levels during autoinﬂammation (e.g., during MS), increasing
the activity of receptors such as mGluR4 that provide a less toxic meta-
bolic pathway to reduce these levels can help address excitotoxicity and
neurodegeneration [11]. Of even greater relevance to our studies, mod-
ulatingmGluR4 signaling on DCs can decrease the expression of activa-
tion markers and alter cytokine secretion proﬁles to suppress TH17-
mediated inﬂammation, while driving T cells toward protective TREG
phenotypes [10,11]. Thus, PHCCC has the potential to help address
both excitotoxicity (by reducing glutamate levels) and inﬂammation
(by redirecting T cell response). Toward this goal, we investigated the
ability of controlled release of PHCCC to improve T cell polarization
with less toxic, lower frequency dosing.
Fig. 6. PHCCC NPs delay the onset of EAE and reduce disease severity. Mice were induced with EAE and treated with 3 mg/kg soluble PHCCC or PHCCC NPs at (A) ﬁve day or (F) three day
intervals. Disease pathologywas assessed daily using the clinical scale described in themethods. (B)Mean clinical score time course formice treated using the regimen in (A). (C) Individual
clinical scores of mice shown in (B) on days 10 and 15. (D) Incidence of disease (EAE score N 0) for the mice in (B). (E) Maximummean score observed during studies using the regimen in
(A). (G) Mean clinical score time course for mice treated using the regimen in (F). (H) Individual clinical scores of mice shown in (G) on days 10 and 15. (I) Incidence of disease (EAE
score N 0) for the mice in (G). (J) Maximummean score observed during studies using the regimen in (F). Studies were conducted with groups of 6 mice. Unpaired T tests were used to
compare between groups at each study day. An alpha value of 0.05 was used to determine signiﬁcance (*).
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erties comparedwith soluble drug. First, PHCCC could be solubilized and
slowly released from NPs without need of solvents or other vehicles
(e.g., sesame oil). PHCCC delivered in particle form was 36-fold less
toxic, with equivalent doses in soluble exhibiting high levels of toxicity
compared to PHCCC NPs (Fig. 1F). Interestingly, PHCCC toxicity was
almost completely eliminated when delivered in NP format, ap-
proaching the levels measured in unstimulated controls. This observa-
tion was true even at the higher concentrations required for PHCCC
NPs tomatch the effectiveness of soluble PHCCC (Fig. 1F). Although tox-
icity was absent when cells were treated with PHCCC NPs, clear effects
on DCs (e.g., surface markers, cytokine proﬁles) and T cells were ob-
served, indicating a modulatory function rather than toxicity or cell
death.
The immunomodulatory effects of soluble PHCCConDCsweremain-
tainedwhen PHCCCwas delivered inNPs, though higher concentrations
had to be delivered to achieve the same level of change in cytokine pro-
ﬁles and activationmarker expression. This observationmay result from
the controlled release of PHCCC from NPs. Soluble PHCCC delivery re-
sults in immediate availability of all drug, while PHCCC is released
from NPs over time (Fig. 1C). DC activation studies lasted 18 h, and
while release studies show that 75% of drugwas released over this inter-
val under sink conditions, without the DMSO vehicle used in soluble
PHCCC treatments, drug release from particles likely achieved a much
lower effective solution concentration of free drug in cell culture wells
compared to the solution concentration in wells treated with soluble
formulations containing DMSO. This idea may also explain why lower
concentrations of PHCCC NPs were more effective than soluble drug in
promoting TREGS, reducing IFNγ, and limiting T cell proliferation during
co-culture studies that continued for 96 h. For example, 400 μM PHCCC
NP had a similar effect to 40 μM soluble PHCCC on reducing DC activa-
tion (Fig. 4A–C), while 50 μM PHCCC NP caused a larger reduction in
T cell proliferation compared to 40 μM soluble PHCCC (Fig. 5A and B).
Soluble drug may be exhausted or degraded over this interval, whereas
drug in particlesmay bemore stable. The greater time formetabolismof
drug in solution could also allow dissolution of more drug as it is re-
leased from particles over this interval, or of drug that has locally
precipitated.Since ﬂuorescent analogs of PHCCC have not been reported, we
studied uptake using NPs loaded with a ﬂuorescent lipophilic dye as a
model cargo. Our results demonstrate that these NPs are readily inter-
nalized by DCs (Fig. 1D and E). Thus, in addition to reduced toxicity,
NP-mediated delivery may provide a simple method of targeting
PHCCC to DCs residing in lymph nodes or spleens since antigen present-
ing cells are specialized to internalize particulate materials over soluble
molecules [18,19]. This possibility is important because DCs present
autoantigens to T cells in lymphoid organs [6–8]. Thus, to polarize
T cell function and ameliorate autoimmune responses, it may be beneﬁ-
cial for immunomodulatory drugs acting on DCs to reach the lymphoid
organs and persist at sufﬁcient concentrations in these tissues during
(self) antigen presentation. Further, soluble delivery results in systemic
exposure of drug, while NPs reach lymph nodes through passive drain-
age and through trafﬁcking by DCs after NP uptake. Using PHCCC NPs
that release PHCCC over an extended time could help target LNs and
avoid systemic exposure while avoiding continual dosing of soluble
drug.
Although PLGA has traditionally been seen as immunologically inert,
recent studies have demonstrated that PLGA can activate DCs and
inﬂammasome pathways, amplify immune responses to toll-like recep-
tor agonists, and cause secretion of inﬂammatory cytokines [30,31].
Thus, empty NP controls were included in all experiments in order to
isolate any intrinsic polymer effects from the encapsulated PHCCC. The
highest masses of empty NPs – correlating to the lowest drug to poly-
mer ratios – generally had a slight suppressive effect on cytokine secre-
tion (Fig. 3), but minimal effects on DC activation (Fig. 4) and T cell
studies (Fig. 5). Interestingly, other reports demonstrate a decrease in
the expression of DC activation markers when DCs are treated with
PLGA particles for 48 h before stimulation with LPS [32]. From a physi-
cochemical standpoint, the slight effects of empty particles observed
in our experiments at high concentrations may be driven by acidiﬁca-
tion of the media from lactic acid byproducts as PLGA degrades [33].
During adaptive immune response, IL-6 and IL-12 drive proinﬂam-
matory function, secreted by DCs to promote TH17 and TH1 cells, respec-
tively [34]. IL-10 is a polyfunctional cytokine, but often serves as a
negative regulator to restrain DC function. Although IL-10 production
is a goal of many tolerogenic therapies, PHCCC has been shown to
177J.M. Gammon et al. / Journal of Controlled Release 210 (2015) 169–178decrease IL-10 production in response to LPS stimulation. The proposed
mechanism for this process is drug-mediated reduction of the cAMP
triggered by LPS, resulting in a shift away from cytokines that
drive TH17 cells and toward cytokines that promote TREG and TH1 [10].
Therefore PHCCC is a modulator, and not a strict immunosuppressive
agent. We observed these effects through a decrease in IL-6 and IL-10 se-
cretion compared to untreated DCs stimulated with LPS (Figs. 2 and 3),
but did not observe any differences in IL-12 secretion (data not shown).
Interestingly, after LPS stimulation, IL-10 secretion was delayed com-
pared with inﬂammatory cytokines (Figs. 2D–F and 3D–F), in agreement
with the natural time course for regulation during which IL-10 supports
return of immune function to basal homeostatic levels following inﬂam-
mation or infection events [34].
The effects of PHCCC on DCs described above have an important
impact on T cell differentiation and function during autoimmunity.
For example, during EAE and MS, disease is driven by subsets of
CD4+ helper T cells, but it is unclear whether TH17 or TH1 cells in-
duce more severe pathology [34]. The Di Marco group has shown
that protective effects of PHCCC treatment on EAE coincide with a
shift away from TH17 cells and toward not only TREG, but also IFNγ-
producing TH1 cells [10]. Our co-culture studies revealed that treat-
ment with PHCCC NPs shifted T cells away from TH17 and toward
TREG phenotypes, while decreasing IFNγ (Fig. 5). Thus, although we
did not observe an increase in TH1 function (e.g., increased IFNγ), de-
creased levels of IFNγ associated with delivery of PHCCC NPs could be
beneﬁcial in reducing the activity of autoreactive T cells during EAE or
other autoimmune diseases [3].
In recent studies, soluble PHCCC protected mice from EAE when
injected daily in sesame oil as a vehicle. However, symptoms rapidly
returned in less than 24 h when treatment was stopped for even a
single day [10]. In our studies, PHCCC NPs delivered every 5 days had
no effect on clinical score compared to mice treated with empty NPs
or soluble PHCCC (Fig. 6A–E). However, when PHCCC NPs were admin-
istered every three days, these particles delayed the onset of EAE and re-
duced the severity of disease compared with soluble drug (Fig. 6F–J) or
emptyNPs (Fig. S3). From a pharmacokinetic perspective, a likely expla-
nation is that NPs do not provide a drug concentration in the therapeutic
window with 5 day intervals, which based on the release studies
(Fig. 1C), appear to be during a time frame over which the drug release
rate is negligible. While release studies indicated ~75% of drug was re-
leased over 8 h, we observed a signiﬁcant reduction in disease progres-
sionwhenmicewere treatedwith PHCCCNPs at three day intervals, but
not when soluble treatments were administered at this frequency.
These effects may have been supported by the slower, but sustained re-
lease from NPs that occurred over 8 to 72 h (Fig. 1c). Owing to the spar-
ing solubility (10 μg/mL), local precipitation of PHCCC due to non-sink
conditions in injected animals may also have slowed the release rate.
Taken together, these ﬁndings highlight the potential of controlled re-
lease to improve the delivery of immunomodulatory signals thatmodu-
late DC metabolism to promote tolerance. These experiments also
underscore the need to develop controlled release formulations that
achieve longer-term release to provide greater reductions in the fre-
quency of injection.
Although treatment with PHCCC NPs successfully delayed the onset
of neurological symptoms, autoimmunity eventually progressed to an
incidence of 100%. Thiswas evident through similarmean clinical scores
in both PHCCC NP and soluble groups at the end of the experiment.
These results are consistentwith ﬁndings from theDiMarco group indi-
cating that PHCCC does not reverse established disease even when sol-
uble PHCCC is administered daily starting one day after the appearance
of neurological symptoms [19]. Thus, controlled release from PHCCC
NPsmay initially be sufﬁcient to delay symptoms, but as the concentra-
tion of PHCCC wanes over the 3 day interval, myelin-reactive events
(e.g., T cell expansion) may increase to cause neurodegeneration that
is not reversed even when another dose of PHCCC NPs is administered.
This idea further highlights the opportunity to use controlled release toenhance metabolic control over DC and T cell function by exploring
polymericmaterials that provide longer term or higher levels of release,
or by incorporating other components such as DC targeting molecules
or more potent mGluR4 enhancers.
5. Conclusion
In this study we utilized an established nanoprecipitation platform
to test the new idea that controlled delivery of a glutamate receptor
enhancer could alter immune cell function to improve autoimmune
therapy. PHCCC NPs exhibited greatly reduced toxicity, while maintain-
ing the immunomodulatory effects of soluble PHCCC on DCs and T cells
in vitro. Treatment of mice with PHCCC NPs delayed disease and de-
creased severity compared to mice treated with soluble PHCCC. More
broadly, this report demonstrates that controlled delivery of metabolic
modulators can be exploited to direct DC function for promoting toler-
ance. This idea could contribute to new therapeutic options for autoim-
munity or inﬂammatory disease.
Acknowledgments
This work was supported in part by NSF CAREER Award # 1351688,
theNationalMultiple Sclerosis Society# PP2103, and the Pharmaceutics
division of the PhRMA Foundation # 13071672. CMJ is a Damon
Runyon-Rachleff Innovator supported by the Damon Runyon Founda-
tion (# DDR3415), a Young Investigator supported by the Alliance for
Cancer Gene Therapy (# 15051543), and a Young Investigator support
by the Melanoma Research Alliance (# 348963). LHT is a NSF Graduate
Research Fellow supported by grant # DGE1322106.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jconrel.2015.05.277.
References
[1] F. Danhier, E. Ansorena, J.M. Silva, R. Coco, A. Le Breton, V. Preat, PLGA-based nano-
particles: an overview of biomedical applications, J. Control. Release 161 (2) (2012)
505–522 (PubMed PMID: WOS:000305790300035. English).
[2] J.I. Andorko, K.L. Hess, C.M. Jewell, Harnessing biomaterials to engineer the lymph
node microenvironment for immunity or tolerance, AAPS J. 17 (2014) 323–338.
[3] D.J. Irvine, M.A. Swartz, G.L. Szeto, Engineering synthetic vaccines using cues from
natural immunity, Nat. Mater. 12 (11) (2013) 978–990 (PubMed PMID:
24150416. Pubmed Central PMCID: 3928825).
[4] A. Lutterotti, S. Yousef, A. Sputtek, K.H. Sturner, J.P. Stellmann, P. Breiden, et al.,
Antigen-speciﬁc tolerance by autologous myelin peptide-coupled cells: a phase 1
trial in multiple sclerosis, Sci. Transl. Med. 5 (188) (2013) 188ra75 (PubMed
PMID: 23740901. Pubmed Central PMCID: 3973034).
[5] L. Steinman, Multiple sclerosis: a coordinated immunological attack against myelin
in the central nervous system, Cell 85 (3) (1996) 299–302 (PubMed PMID:
8616884).
[6] H.F. McFarland, R. Martin, Multiple sclerosis: a complicated picture of autoimmuni-
ty, Nat. Immunol. 8 (9) (2007) 913–919 (PubMed PMID: 17712344).
[7] M. Comabella, S.J. Khoury, Immunopathogenesis of multiple sclerosis, Clin.
Immunol. 142 (1) (2012) 2–8 (PubMed PMID: WOS:000299912600002. English).
[8] D. Pitt, P. Werner, C.S. Raine, Glutamate excitotoxicity in a model of multiple sclero-
sis, Nat. Med. 6 (1) (2000) 67–70 (PubMed PMID: WOS:000084583300037.
English).
[9] B.D. Trapp, K.A. Nave, Multiple sclerosis: an immune or neurodegenerative disorder?
Annu. Rev. Neurosci. 31 (2008) 247–269 (PubMed PMID: WOS:000257992200011.
English).
[10] L. Peferoen, M. Kipp, P. van der Valk, J.M. van Noort, S. Amor, Oligodendrocyte-
microglia cross-talk in the central nervous system, Immunology 141 (3) (2014)
302–313 (PubMed PMID: WOS:000330811600003. English).
[11] S.F. Spampinato, S. Merlo, M. Chisari, F. Nicoletti, M.A. Sortino, Glial metabotropic
glutamate receptor-4 increases maturation and survival of oligodendrocytes,
Front. Cell. Neurosci. 8 (2014) 462 (PubMed PMID: 25642169. Pubmed Central
PMCID: 4294134).
[12] M. Maj, V. Bruno, Z. Dragic, R. Yamamoto, G. Battaglia, W. Inderbitzin, et al., (−)-
PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of
action, and neuroprotection, Neuropharmacology 45 (7) (2003) 895–906 (PubMed
PMID: WOS:000186378800002. English).
178 J.M. Gammon et al. / Journal of Controlled Release 210 (2015) 169–178[13] M. Julio-Pieper, P.J. Flor, T.G. Dinan, J.F. Cryan, Exciting times beyond the brain: me-
tabotropic glutamate receptors in peripheral and non-neural tissues, Pharmacol.
Rev. 63 (1) (2011) 35–58 (PubMed PMID: WOS:000287356800002. English).
[14] R.M. Steinman, H. Hemmi, Dendritic cells: translating innate to adaptive immunity,
Curr. Top. Microbiol. 311 (2006) 17–58 (PubMed PMID: WOS:000241815600002.
English).
[15] R.M. Steinman, D. Hawiger, M.C. Nussenzweig, Tolerogenic dendritic cells, Annu. Rev.
Immunol. 21 (2003) 685–711 (PubMed PMID: WOS:000182523500021. English).
[16] A.E. Morelli, A.W. Thomson, Tolerogenic dendritic cells and the quest for transplant
tolerance, Nat. Rev. Immunol. 7 (8) (2007) 610–621 (PubMed PMID: WOS:
000248394100013. English).
[17] A. Lutterotti, R. Martin, Antigen-speciﬁc tolerization approaches in multiple
sclerosis, Expert Opin. Investig. Drugs 23 (1) (2014) 9–20 (PubMed PMID:
WOS:000328110700002. English).
[18] R. Pacheco, H. Oliva, J.M. Martinez-Navio, N. Climent, F. Ciruela, J.M. Gatell, et al., Glu-
tamate releasedby dendritic cells as a novelmodulator of T cell activation, J. Immunol.
177 (10) (2006) 6695–6704 (PubMed PMID: WOS:000242009700017. English).
[19] F. Fallarino, C. Volpi, F. Fazio, S. Notartomaso, C. Vacca, C. Busceti, et al., Metabotropic
glutamate receptor-4 modulates adaptive immunity and restrains neuroinﬂamma-
tion, Nat. Med. 16 (8) (2010) 897-U94 (PubMed PMID: WOS:000280649200029.
English).
[20] F. Fazio, C. Zappulla, S. Notartomaso, C. Busceti, A. Bessede, P. Scarselli, et al.,
Cinnabarinic acid, an endogenous agonist of type-4 metabotropic glutamate recep-
tor, suppresses experimental autoimmune encephalomyelitis in mice, Neurophar-
macology 81 (2014) 237–243 (PubMed PMID: WOS:000335632400025. English).
[21] R.S. Lopez-Diego, H.L. Weiner, Novel therapeutic strategies for multiple sclerosis— a
multifaceted adversary, Nat. Rev. Drug Discov. 7 (11) (2008) 909–925 (PubMed
PMID: WOS:000260532400022. English).
[22] C.M. Niswender, K.A. Johnson, C.D. Weaver, C.K. Jones, Z.X. Xiang, Q.W. Luo, et al.,
Discovery, characterization, and antiparkinsonian effect of novel positive allosteric
modulators of metabotropic glutamate receptor 4, Mol. Pharmacol. 74 (5) (2008)
1345–1358 (PubMed PMID: WOS:000260197300017. English).
[23] E. Bettelli, M. Pagany, H.L. Weiner, C. Linington, R.A. Sobel, A.K. Kuchroo, Myelin ol-
igodendrocyte glycoprotein-speciﬁc T cell receptor transgenic mice develop sponta-
neous autoimmune optic neuritis, J. Exp. Med. 197 (9) (2003) 1073–1081 (PubMed
PMID: WOS:000182752000002. English).
[24] I. Mendel, N. Kerlero de Rosbo, A. Ben-Nun, A myelin oligodendrocyte glycoprotein
peptide induces typical chronic experimental autoimmune encephalomyelitis in
H-2b mice: ﬁne speciﬁcity and T cell receptor V beta expression of encephalitogenic
T cells, Eur. J. Immunol. 25 (7) (1995) 1951–1959 (PubMed PMID: 7621871).[25] T. Korn, J. Reddy, W. Gao, E. Bettelli, A. Awasthi, T.R. Petersen, et al., Myelin-speciﬁc
regulatory T cells accumulate in the CNS but fail to control autoimmune inﬂamma-
tion, Nat. Med. 13 (4) (2007) 423–431 (PubMed PMID: 17384649. Pubmed Central
PMCID: 3427780).
[26] M. Look, E. Stern, Q.A. Wang, L.D. DiPlacido, M. Kashgarian, J. Craft, et al., Nanogel-
based delivery of mycophenolic acid ameliorates systemic lupus erythematosus
in mice, J. Clin. Invest. 123 (4) (2013) 1741–1749 (PubMed PMID: WOS:
000317021800033. English).
[27] S. Jhunjhunwala, G. Raimondi, A.W. Thomson, S.R. Little, Delivery of rapamycin to
dendritic cells using degradable microparticles, J. Control. Release 133 (3) (2009)
191–197 (PubMed PMID: 19000726. Pubmed Central PMCID: 2925512).
[28] R.A. Maldonado, R.A. LaMothe, J.D. Ferrari, A.H. Zhang, R.J. Rossi, P.N. Kolte, et al.,
Polymeric synthetic nanoparticles for the induction of antigen-speciﬁc immunolog-
ical tolerance, Proc. Natl. Acad. Sci. U. S. A. 112 (2) (2015) E156–E165 (PubMed
PMID: WOS:000347732300010. English).
[29] A. Yeste, M. Nadeau, E.J. Burns, H.L. Weiner, F.J. Quintana, Nanoparticle-mediated
codelivery of myelin antigen and a tolerogenic small molecule suppresses experi-
mental autoimmune encephalomyelitis, Proc. Natl. Acad. Sci. U. S. A. 109 (28)
(2012) 11270–11275 (PubMed PMID: WOS:000306642100052. English).
[30] F.A. Sharp, D. Ruane, B. Claass, E. Creagh, J. Harris, P. Malyala, et al., Uptake of partic-
ulate vaccine adjuvants by dendritic cells activates the NALP3 inﬂammasome,
Proc. Natl. Acad. Sci. U. S. A. 106 (3) (2009) 870–875 (PubMed PMID: WOS:
000262809700037. English).
[31] J. Park, J.E. Babensee, Differential functional effects of biomaterials on dendritic cell
maturation, Acta Biomater. 8 (10) (2012) 3606–3617 (PubMed PMID: WOS:
000309301400007. English).
[32] J.S. Lewis, C. Roche, Y. Zhang, T.M. Brusko, C.H. Wasserfall, M. Atkinson, et al., Com-
binatorial delivery of immunosuppressive factors to dendritic cells using dual-sized
microspheres, J. Mater. Chem. B 2 (17) (2014) 2562–2574 (PubMed PMID: WOS:
000334121500023. English).
[33] E. Gottfried, L.A. Kunz-Schughart, S. Ebner, W. Mueller-Klieser, S. Hoves, R.
Andreesen, et al., Tumor-derived lactic acid modulates dendritic cell activation
and antigen expression, Blood 107 (5) (2006) 2013–2021 (PubMed PMID: WOS:
000235632700046. English).
[34] R. Samarasinghe, P. Tailor, T. Tamura, T. Kaisho, S. Akira, K. Ozato, Induction of
an anti-inﬂammatory cytokine, IL-10, in dendritic cells after toll-like receptor sig-
naling, J. Interf. Cytokine Res. 26 (12) (2006) 893–900 (PubMed PMID: WOS:
000243076600006. English).
